NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization<
21 Apr 2026

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data
Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates<
20 Apr 2026

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Multiple clinical and regulatory updates for the Company's pipeline of first- and best-in-class ADCs.
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science<
17 Apr 2026

UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

Total transaction value of up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments.
Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline<
15 Apr 2026

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Ysios Capital joins Adcendo’s $75M Series C financing round
Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation<
27 Mar 2026

Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation

InceptionBio has completed its first closing with CDTI backing and targets the creation of at least three biotech companies by 2026.
Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical<
18 Mar 2026

Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical

New vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.
NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben<
03 Mar 2026

NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben

Orziloben granted Orphan Drug Designation in the U.S. and European Union.
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy<
09 Feb 2026

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

The NYRVANA first-in-human trial is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology<
09 Feb 2026

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology
Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España<
20 Jan 2026

Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España

El vehículo, gestionado por Andbank Wealth Management y asesorado por Ysios Capital, registra un retorno neto del 52,5% desde su lanzamiento en febrero de 2025.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.